Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Abstract

BACKGROUND The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin. Aspirin inhibits platelet activation by inhibiting platelet cyclooxygenase and thromboxane production, and reduces the odds of a serious vascular event by about a quarter. The… (More)

Topics

Cite this paper

@article{Hankey2000ThienopyridineD, title={Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.}, author={Graeme J. Hankey and Catherine L Sudlow and David Dunbabin}, journal={The Cochrane database of systematic reviews}, year={2000}, volume={2}, pages={CD001246} }